IP Library Granted Patent US 6,849,458
Granted Patent B2
US 6,849,458 · App. 09/801,676 · Granted Feb 1, 2005

Microplate thermal shift assay apparatus for ligand development and multi-variable protein chemistry optimization

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,849,458
App. No.
09/801,676
Granted
Feb 1, 2005
Kind
B2
Abstract

The present invention provides an assay apparatus for that includes a temperature adjusting means for simultaneously heating a plurality of samples, and a receiving means for receiving spectral emission from the samples while the samples are being heated. In further aspects of the invention, the receiving means can be configured to receive fluorescent emission, ultraviolet light, and visible light. The receiving means can be configured to receive spectral emission from the samples in a variety of ways, e.g., one sample at a time, simultaneously from more than one sample, or simultaneously from all of the samples. The temperature adjusting means can be configured with a temperature controller for changing temperature in accordance with a predetermined profile.

Claims (247)

1. A method for identifying a ligand that binds to a protein, comprising the steps of:

(1) receiving unfolding data that indicates thermal unfolding as a function of temperature for a protein incubated with a molecule tested for binding;

(2) determining an unfolding temperature midpoint for the protein in the presence of the molecule from the unfolding data;

(3) comparing the unfolding temperature midpoint for the protein incubated with the ligand with the unfolding temperature midpoint for the protein in the absence of any molecules tested for binding; and

(4) determining that the molecule tested for binding binds to the protein when a difference between the unfolding temperature midpoint for the protein in the presence of the molecule and unfolding temperature midpoint for the protein in the absence of any molecules tested for binding exceeds a threshold; and

(5) estimating the ligand binding affinity at the unfolding temperature midpoint according to:

K

L

T

m

=

exp

{

-

Δ

H

u

T

0

R

[

1

T

m

-

1

T

0

]

+

Δ

C

pu

R

[

ln

(

T

m

T

0

)

+

T

0

T

m

-

1

]

}

[

L

T

m

]

where,

Kf L T m is a ligand association constant at T m

T m is a midpoint temperature for the protein unfolding transition in the presence of the ligand;

T 0 is a midpoint temperature for the protein unfolding transition in the presence of the ligand;

ΔH u T 0 is an enthalpy of protein unfolding in the absence of ligand at T 0 ;

ΔC pu is a change in heat capacity upon protein unfolding in the absence of ligand;

[L T m ] is a free ligand concentration at T m ;and

R is the gas constant.

2. The method according to claim 1 , further comprising the step of:

(6) inserting actual values ΔH u T 0 and ΔC pu into the equation of step (5).

3. The method according to claim 1 , further comprising the step of:

(6) estimating values for ΔH u T 0 and ΔC pu for use in the equation of step (5).

4. The method according to claim 3 , wherein step (6) comprises the steps of:

(a) fitting the data with a least squares algorithm according to:

y

(

T

)

=

y

u

+

(

y

f

-

y

u

)

1

+

exp

[

[

-

Δ

H

u

R

]

[

1

T

-

1

T

m

]

+

[

Δ

C

pu

R

]

[

(

T

m

T

-

1

)

+

ln

T

T

m

]

]

where,

y(T) is fluorescence unfolding data as a function of temperature T;

Y u is a pre-transitional fluorescence intensity,

y f is a post-transitional fluorescence intensity;

ΔH u is a protein unfolding enthalpy;

ΔC pu is a change in heat capacity upon protein unfolding;

T m is a midpoint temperature for protein unfolding transition in the presence of the ligand; curve fit

(b) varying values for, y u , y f , ΔH u , ΔC pu , and ΔC pu until a suitable is obtained; and

(c) using resultant values from step 9(b) in step (5).

5. The method according to claim 1 , further comprising the step of:

(6) determining a ligand binding constant, for any temperature T, according to:

K

L

T

=

K

L

T

m

exp

{

-

Δ

H

L

T

R

[

1

T

-

1

T

m

]

+

Δ

C

pL

R

[

ln

(

T

T

m

)

-

T

T

m

+

1

]

}

.

6. A method for identifying a ligand that binds to a protein, comprising the step of:

(1) receiving unfolding data that indicates thermal unfolding as a function of temperature for a protein incubated with a molecule tested for binding;

(2) determining an unfolding temperature midpoint for the protein in the presence of the molecule from the unfolding data;

(3) comparing the unfolding temperature midpoint for the protein incubated with the ligand with the unfolding temperature midpoint for the protein in the absence of any molecules tested for binding; and

(4) determining that the molecule tested for binding binds to the protein when a difference between the unfolding temperature midpoint for the protein in the presence of the molecule and unfolding temperature midpoint for the protein in the absence of any molecules tested for binding exceeds a threshold; and

(5) estimating the ligand binding affinity at the unfolding temperature midpoint; and

(6) determining a ligand binding constant, for any temperature T, according to:

K

L

T

=

K

L

T

m

exp

{

-

Δ

H

L

T

R

[

1

T

-

1

T

m

]

}

.

7. The method according to claim 5 , wherein step (1) further comprises the step of plotting thermal unfolding according to a non-linear, least square fitting algorithm.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 6, 2010
From: JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT, L.L.C.
To: LIFE TECHNOLOGIES CORPORATION
Reel/Frame 025451/0597 →
MERGER Recorded Nov 11, 2010
From: 3-DIMENSIONAL PHARMACEUTICALS, INC.
To: JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT, L.L.C.
Reel/Frame 025351/0202 →
EXECUTIVE ORDER 9424, CONFIRMATORY LICENSE Recorded Apr 11, 2008
From: THREE-DIMENSIONAL PHARMACEUTICALS, INC
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 020792/0826 →
MERGER Recorded May 3, 2005
From: 3-DIMENSIONAL PHARMACEUTICALS, INC.
To: JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT, L.L.C.
Reel/Frame 015972/0106 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 3, 2005
From: PETRELLA, EUGENIO C.; PANTOLIANO, MICHAEL W.; RHIND, ALEXANDER W.; SALEMME, FRANCIS R.; SPRINGER, BARRY A.
To: 3-DIMENSIONAL PHARMACEUTICALS, INC.
Reel/Frame 015972/0148 →
Continuity (4)
Continuation 0945999600 · Dec 14, 1999
Continuation 0885345900 · May 9, 1997
Provisional Application 6001786000 · May 9, 1996
Related Publication 20020114734A1 · Aug 22, 2002